Purchase this article with an account.
E. Setrouk, T. Garcia, V. Grue, A. Ducasse, C. F. Arndt; Photodynamic Therapy With Low Dose Verteporfin in Chronic Idiopathic Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1343.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
In chronic idiopathic central serous chorioretinopathy (ICSC), recent studies indicate that photodynamic therapy (PDT) could be effective in subretinal fluid resorption with reduced dose of verteporfin (3mg/m2) and reduced fluence PDT. However safety and cost issues remain to be addressed. This retrospective non randomized study has been designed to evaluate the efficacy of a further reduced dose of verteporfin for PDT in chronic ICSC.
Patients with chronic ICSC greater than 3 months of documented duration were included. Visual acuity had to be <20/40. The patients were assigned to 2 treatment groups. They received either 3 mg/m2 or 1,5 mg/m2 verteporfin and reduced fluence PDT. All patients had visual acuity, ocular coherent tomography (OCT), fluorescein and indocyanine green (ICG) angiography on inclusion, follow up was based on ETDRS and OCT at 6 weeks, 3 and 6 months.
Seven patients (eight eyes) were included. Mean duration of symptoms prior to PDT was 6 months. After a 6 month follow-up, no significant difference between the 2 groups was observed: the reduction of mean foveal thickness was equivalent in both groups, OCT showed a reduction in serous detachment of more than 100 microns in only one of 8 eyes. Visual acuity increased by more than 5 ETDRS letters in only 3 eyes.
Our preliminary data suggest that resolution of serous detachments and visual improvement in patients with chronic ICSC treated with a low dose of verteporfin (both 3mg/m2 and 1,5mg/m2) may not be favorable in all cases..
This PDF is available to Subscribers Only